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(range8 to 27), no patienthad a recurrenceof symptomatic
tachycardia(successrate95%confidenceinterval65%to 100%).
Conclusions.S1OWpathwayablationmaybeclinicallyusefulin
patientswith documentedbut noninduciblePSVTwho have
evidenceofdualAVnodepathways.
(JAnr COUCardiol1996;28:1000-4)
Patientswho have had documentedepisodesof paroxysmal
supraventriculartachycardia(PSVT) at times do not have
inducibletachycardiain theelectrophysiologylaboratory(1,2).
The presenceof dual atrioventricular(AV) node pathways,
whichserveasthesubstrateforAVnodereentranttachycardia
(AVNRT),suggestsa possiblepredilectionfor this type of
tachycardia.Furthermore,AVNRTmaynot alwaysbe repro-
ducibly inducible.Accordingly,an American College of
Cardiology/AmericanHeart Association(ACC/AHA)task
force report on guidelinesfor clinicalelectrophysiologicand
catheterablationproceduresconcludedthat evidenceof dual
AV nodepathwaysin patientswitha historyof PSVTtachy-
cardiawho do not haveinducibletachycardiain the electro-
physiologylaboratorymaybe an indicationfor slowpathway
ablation(3). However,evidenceof dual AV node pathways
maybe presentin individualswhohaveneverhadPSVT(4,5),
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and no previousstudieshave demonstratedor assessedthe
valueof slowpathwayablationin patientswith documented
but noninduciblePSVT.Therefore,the purposeof this pro-
spectivestudywasto assesstheclinicalefficacyofslowpathway
ablationin patientswithdocumentedepisodesof PSVTwho




seven consecutivepatientswho met the followingcriteria:
recurrentepisodesof PSVTdocumentedby an electrocardio-
graphic(ECG)recording;the absenceof induciblePSVTboth
in the baselinestateand afterthe administrationof isoproter-
enolandatropine;the absenceofanyevidenceofan accessory
pathway;the presenceof a slowAV node pathway,as mani-
festedby either dualAV node physiologyor AV node echo
beats.Duringthe timethat thesesevenpatientswererecruited
for this study,324 other patientswith a historyof PSVT
underwentan electrophysiologicprocedureandwerefoundto
haveinducibleAVNRT.
The clinicalcharacteristicsof the sevenpatients in this
studyaredescribedinTable1.Therewerefivewomenandtwo
menwitha mean(*SD) ageof33 t 12years.Theyhadbeen
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symptomaticfromPSVTfor 12 t 12years.The incidenceof
episodesof PSVTrangedfromat leastonceper dayto once
permonth,withthedurationofepisodesrangingfrom5minto
4h.Threepatientshada historyofsyncopein associationwith
an episodeof PSVT. Based on a physicalexamination,a
12-leadECG, and an echocardiogram,none of the patients
had anyevidenceof structuralheart disease.
Withinthe5yearsbeforetheelectrophysiologicprocedure,
fivepatientshad required13323 (range1 to 60)emergency
roomvisitsbecauseofpersistentepisodesofPSVT.In threeof
thesepatients,the tachycardiawasterminatedbyeitheraden-
osineor verapamiladministeredintravenously.In the other
twopatients,the tachycardiaterminatedspontaneouslybefore
the administrationof medication.In these fivepatients,the
PSVTwasrecordedon a 12-leadECGor rhythmstrip(Fig.1).
In the other twopatients,at leastone episodeof PSVTwas
documentedwith a Helter monitor or a continuousloop
recorder (Fig. 2). The rate of the documentedepisodesof
PSVTrangedfrom170to 260beats/rein,anddiscreteP waves
werenot apparent.A mean of 3 i 3 antiarrhythmicmedica-
tions had been prescribedbefore referral. Before referral,
three patientsalreadyhad undergoneone electrophysiologic
test,whichhad demonstratedno induciblePSVT.
Electrophysiologictestingand catheterablation.Electro-
physiologictestswere performedin the postabsorptivestate
Table 1. ClinicalFeatures of SevenPatients With Spontaneousbut
NoninducibleParoxysmalSupraventricularTachycardia
Pt DurationofPSVT No.ofAA Incidence
No. Age(yr)/Gender (yr) Meals (episodes/mo)
1 24/F 7 2 120
2 51/F 10 6 1
3 45iF 30 7 4
4 221M 2 3 4
5 15IM I 8 30
6 4oiF 23 5 10
7 321F 0.2 1 3
AAMeals= antiarrhythmicmedications;F = female;M = male;PSVT=
paroxysmalsupraventriculartachycardia;Pt = patient.
afterwritteninformedconsentwasobtainedand after antiar-
rhythmicdrug therapyhad been discontinuedfor at least 5
half-lives.Three 7F quadripolarelectrode catheters were
insertedin a femoralvein and positionedin the high right
atrium,the Hisbundleposition,and the rightventricle.Leads




Atrial and ventricularoverdrivepacingand programmed
stimulationwereperformedto determinethe conductionand
refractorinesspropertiesof the AV node, to rule out the
presenceof an accessorypathwayand to inducesupraventric-
ular tachycardia.Attemptsto inducesupraventriculartachy-
cardia by atrial and ventricularoverdrivepacing and pro-
grammedstimulationwere repeatedduringa 2- to 8-@min
Figure 1. Electrocardiogram recorded in the emergencyroom during
symptomatictachycardia in Patient 2.Therateofthetachycardias
160beats/rein, and discrete P wavesare not present.
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Figure2. Anepisode of symptomatictachycardia recorded
in Patient 5with a continuous loop monitor. The tachycar-
dia occurred during exercise.The rate of the tachycardia is
250beats/rein, and P waves are not seen.
infusionofisoproterenoltitratedto resultina sinusrateof 120
to 130beats/rein,and againafter the intravenousadministra-
tion of 0.8 to 1.5 mg of atropine.In accordancewith the
selectioncriteria for this study,none of the patients had
induciblePSVTor evidenceof an accessorypathway,but all
patientshad evidenceof dual AV node pathways.This evi-
denceconsistedofeitherdualAVnodephysiology,definedas
an incrementof 50 ms or more in the A2H2intervalin
associationwitha 10-msdecrementin theA1A2interval(6,7),
or thepresenceofAVnodeechobeats.Atrioventricularnode
echo beats were definedas reproducibleecho beats during
programmedatrialstimulationwhichwerecoincidentwiththe
QRScomplex,whichhad a concentricpatternof atrialactiva-
tion and which occurred with prolongationof the A2H2
intervalto =200ms (Fig.3).
Radiofrequeneycatheterablationof the slowpathwaywas
performedwith a catheterthat had a 4-mmdistalelectrode
anda deflectabletip (MansfieldEP or EP Technologies)using
a combinedanatomicand electrogrammappingapproach(8).
Radiofrequeneyenergywasdeliveredat 500kHz as a contin-
uoussinewaveat powersettingsof 5 to 50W (EP Technolo-
Figure3.Anexampleof a singleatrioventricularnode echo beat (A’)
induced by programmed stimulationwith a single atrial extrastimulus
(S2).Note that the echo beat has a concentric atrial activation
sequence and is coincident with the QRS complex. The atrial-His
interval immediatelypreceding the echo beat is 200ms. HBE = His
bundle electrogram; HRA = high right atrium; RV = right ventricle;







gies). The end point of the ablation procedure was the
eliminationof slowpathwayfunction,manifestedas elimina-




monthsafter the ablationprocedure.The follow-upperiod




the meanvalue t SD and were comparedusinga ttest for
pairedvariables.The McNemartestwasusedto comparethe





with the correspondingvaluesin a concurrentgroup of 34
consecutivepatients who underwent an electrophysiologic








Baseline 417? 78 365t 79 0.1
Isoproterenol 277? 23 263? 34 0.2
VABCL(ins)
Baseline 375t 115 365? 92 0.9
Isoproterenol 247~ 27 264? 40 0.9
AVNERP(ins)
Baseline 364t 44 287? 76 0.9
Isoproterenol 236? 10 201? 62 0.8
Dataare expressedasmeanvaluet SD.AVBCL= atrioventricularblock
cyclelength;AVNERP = atrioventricularnodeeffectiverefractoryperiod;
VABCL= ventriculoatnalblockcyclelength.
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Baseline 417? 78 377t 43 0.2
Isoproterenol 277t 23 280? 14 0.4
VABCL(ins)
Baseline 375? 115 318? 20 0.4
IsoproterenoJ 247227 294? 36 0.2
AVNERP(ins)
Baseline 364~ 44 326*39 0.3
Isoproterenol 236? 10 263? 43 0.4
DualAVNphysiology
Baseline 6 1 0.025
Isoproterenol 5 0 0.025
AVNecho
Baseline 4 0 0.05
Isoproterenol 6 0 <0,02
Data are expressedas meanvaluet SDor numberof patients.AVN=
atrioventricularnode;otherabbreviationsas inTable2.
Results
Atrioventricularnode properties.The mean AV block
cyclelength,the AV nodeeffectiverefracto~ periodand the
ventriculoatrialblockcyclelengthin the sevenpatientsin this
study are shown in Table 2. These values did not differ
significantlyfromthecorrespondingvaluesin34otherpatients
whodid haveinducibleAVNRT(Table2).
Beforeablation,each of the sevenpatientshad dualAV
nodephysiologyor singleAVnodeechobeats,or both,either
inthebaselinestateor duringisoproterenolinfusion(Table3).
S1OWpathwayablation.A mean of 9 ~ 4 applicationsof
radiofrequeneyenergy(meanduration49 * 13s)weredeliv-
eredat a meanpowerof36t 7W.Themeanfluoroscopetime
was 20 3 7 min. No complicationsoccurred during the
procedure.The electrophysiologicmeasurementsbefore and
after slowpathwayablationare displayedin Table 3. All
evidenceof dual AV node pathwayswas eliminatedin six
patients.The maximalA2H2intervalin these patientsde-





diaduringa meanfollow-upperiodof 15? 10months(range
8 to 27,successrate 95%confidenceinterval65%to 100%).
Discussion
Main findings.The resultsof this studydemonstratethe
clinicalutilityof slowpathwayablationin patientswho have
had spontaneousepisodesofPSVTandwhohaveevidenceof
dualAVnodepathwaysbut no induciblePSVTin the electro-
physiologylaboratory.Slowpathwayablationwaseffectivein
eliminatingrecurrencesof symptomatictachycardia,implying
that these patients had been symptomaticfrom AVNRT,
which could not be induced during the electrophysiologic
proceduredespitethe use of isoproterenoland atropine.The
incidenceof noninducibilityamongpatientswithspontaneous
episodesof AVNRTappearsto be -2Y0.
Possiblereasonsfor noninducibilityofAVNRT,A signifi-
cantproportionofpatientswhoundergoan electrophysiologic
procedurebecauseof a historyofPSVTdo not haveinducible






in thisstudycontinuedto not haveinducibleAVNRTdespite
the use of isoproterenoland atropine.
The presenceof excellentventriculoatrialconductionand




the noninducibilityof tachycardia.Inadequate anterograde
delayin theslowpathwayisalsoanunlikelyexplanationforthe
noninducibilityof tachycardia,in lightof the occurrenceof
retrogradefastpathwayconductionand singleAV nodeecho
beatsin eachpatient.Anterogradeblockin the slowpathway
afterretrogradeconductionthroughthe fastpathwaysuggests
that relativelyslowanterogradeslowpathwayconductionor
the inabilityof the slowpathwayto adaptto a suddenincrease
in rate was the factor which prevented the inductionof
AVNRT.Thiswouldbe consistentwith the findingthat the
meanAVblockcyclelengthtendedtobe longerinthepatients
in thisstudythaninotherpatientswhohadinducibleAVNRT.
It is possiblethat neither isoproterenolnor atropine ade-
quatelyreproducedthe autonomicstate which allowedfor
spontaneousepisodesof AVNRToutsideof the electrophysi-
ologylaboratory.
Other possiblereasons for noninducibility.In patients
who have had documentedepisodesof a supraventricular
tachycardiawitha regularrate butwhodo not haveinducible
PSVTin the electrophysiologylaborato~, possibleexplana-
tionsotherthanAVNRTincludeautomaticatrialtachycardia,
intraatrialreentranttachycardianot inducibleat the time of
theelectrophysiologicprocedureor atrialflutterwith1:1or 2:1
conductionin whichthe flutterwavesare not apparentand
whichmimicsPSVT.Therefore,it shouldnotbe assumedthat
slowpathwayablationwillbe therapeuticin all patientswith
spontaneousbut noninduciblePSVT. Electrocardiographic
findingsoftencandistinguishatrialtachycardiafromAVNRT,
thereby identifyingpatients unlikelyto benefit from slow
pathwayablation.In the patients in this study, the ECG
recordingsof spontaneousepisodesof tachycardiawere all
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tachycardiabefore performingan electrophysiologicproce- patientswithspontaneousbut noninduciblePSVTas a classI
dure,wheneverpossible,in patientswhohavehad PSVT. indicationfor slowpathwayablation.
Study limitations.A limitationof this study is that the
samplesizeconsistedof onlysevenpatients.However,these
sevenpatientswere drawnfrom a pool of 324patientswith





first validationfor the recommendationby the ACC/AHA
Committeeon ClinicalIntracardiacElectrophysiologicand
CatheterAblationProceduresthat slowpathwayablationmay
be indicatedin patientswith spontaneousepisodesof PSVT
whohaveevidenceof dualAV nodepathwaysbut noninduc-
iblePSVTin the electrophysiologylaboratory.Thecommittee
consideredthepresenceofdualAVnodepathwaysinpatients
with spontaneousbut noninduciblePSVT to be a class II
indicationforslowpathwayablation,reflectingtheuncertainty
and dividedopinionthat has existedregardingthe clinical
utilityof slowpathwayablationin this setting(3). However,
becausethe resultsof the presentstudyclearlydemonstrate
clinicalbenefit to the patient, and althoughconfirmatory
studies are necessary,it may be appropriateto consider
reclassifyingthe presence of dual AV node pathwaysin
1. HuyckeEC, Lai WT, NguyenNX,KeungEC,SungRJ. Roleof intravenous
isoproterenolin the electrophysiologicinductionof atrioventricularnode
reentranttachycardiain patientswithdualatrioventricularnodepathways.
ArnJ Cardiol1989;64:1131-7.
2. Wu D, DenesP, BauemfeindR, DhingraRC, WyndhamC, RosenKM.
Effectsof atropineon inductionandmaintenanceof atrioventricrdarnodal
reentranttachycardia.Circulation1979;59:779-88.
3. ZipesDP,DimarcoJP,GillettePC,JackrnanWM,MyerburgRJ,Rahmitoola
SH. Guidelinesfor clinicalintracardiacelectrophysiologicaland catheter
ablationprocedures.J AmCoilCardiol1995;26:555-73.
4. CastaA,WolffG, MehtaAV,et al.Dualatrioventricularnodalpathways:a
benignfindingin arrhythmia-freechildrenwithheartdisease.AmJ Cardiol
1980;46:1013-8.







of anatomicand electrogrammappingapproachesto ablationof the slow
pathwayof atrioventricularnodereentranttachycardia.J AmCoilCardiol
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